OncoBeta® GmbH, a commercial-stage medical device company specialised in innovative epidermal radioisotope therapies is pleased to announce that it has formalised its manufacturing partnership with ANSTO.
Following the completion of all regulatory approvals, ANSTO will produce OncoBeta's novel RheniumSCT® therapeutic for the treatment of non-melanoma skin cancer. OncoBeta® GmbH expects to launch Rhenium-SCT® by late 2021.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year
OncoBeta's Rhenium-SCT® will offer a new and highly effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, Chief Operating Officer at OncoBeta® GmbH and CEO of OncoBeta International GmbH stated: "This is a huge step forwards for our organization. We are very excited to bring our technology to Australia and ANSTO is a key partner of ours in the goal of helping thousands of Australians afflicted with non-melanoma skin cancer."
Mar Olmeda Palomar, Medical Engineering Manager at OncoBeta® GmbH stated: "After the successful commissioning of the production line at ANSTO, we are more confident than ever in our partnership with them. It's been a pleasure to work closely with ANSTO's experienced and motivated team. We believe they are the best partner to help
